Bioshares Biotechnology Clinical Trials Fund ETF Forecast

Buy or Hold candidate since Jun 08, 2026 Gain 29.67%

The BioShares Biotechnology Clinical Trials ETF price fell by -3.34% on the last day (Friday, 10th Jul 2026) from $54.87 to $53.04. During the last trading day the ETF fluctuated 3.54% from a day low at $51.80 to a day high of $53.64. The price has risen in 7 of the last 10 days and is up by 6.84% over the past 2 weeks. Volume has increased on the last day by 8 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 40 thousand shares were bought and sold for approximately $2.13 million.

The ETF lies in the upper part of a very wide and strong rising trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break-up at the top trend line at $54.96 will firstly indicate a stronger rate of rising. Given the current short-term trend, the ETF is expected to rise 11.78% during the next 3 months and, with a 90% probability hold a price between $47.58 and $61.44 at the end of this 3-month period.

BBC Signals & Forecast

The BioShares Biotechnology Clinical Trials ETF holds a sell signal from the short-term Moving Average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the ETF giving a positive forecast for the ETF. On further gains, the ETF will meet resistance from the short-term Moving Average at approximately $53.12. On a fall, the ETF will find some support from the long-term average at approximately $46.35. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Thursday, July 09, 2026, and so far it has fallen -3.34%. Further fall is indicated until a new bottom pivot has been found. Volume rose on falling prices yesterday. This may be an early warning and the ETF should be followed more closely.

Support, Risk & Stop-loss for BioShares Biotechnology Clinical Trials ETF

On the downside, the ETF finds support just below today's level from accumulated volume at $46.00 and $44.83. There is a natural risk involved when a ETF is testing a support level, since if this is broken, the ETF then may fall to the next support level. In this case, BioShares Biotechnology Clinical Trials finds support just below today's level at $46.00. If this is broken, then the next support from accumulated volume will be at $44.83 and $41.06.

This ETF may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this ETF is considered to be "high risk". During the last day, the ETF moved $1.84 between high and low, or 3.54%. For the last week, the ETF has had daily average volatility of 2.69%.

Our recommended stop-loss: $51.01 (-3.81%) (This ETF has high daily movements and this gives high risk. There is a sell signal from a pivot top found 1 day ago.)

Trading Expectations (BBC) For The Upcoming Trading Day Of Monday 13th

For the upcoming trading day on Monday, 13th we expect BioShares Biotechnology Clinical Trials Fund to open at $52.82, and during the day (based on 14 day Average True Range), to move between $52.22 and $53.85, which gives a possible trading interval of +/-$1.62 (+/-3.11%) up or down from last closing price. If BioShares Biotechnology Clinical Trials Fund takes out the full calculated possible swing range there will be an estimated 3.11% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $54.20 (2.20%) than the support at $46.00 (13.26%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is BioShares Biotechnology Clinical Trials Fund ETF A Buy?

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for BioShares Biotechnology Clinical Trials ETF to perform well in the short-term. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this ETF since the last evaluation from a Strong Buy to a Buy candidate.

Current score: 1.516 Buy Candidate Downgraded

Predicted Fair Opening Price

Predicted fair opening price on July 13, 2026 - $52.82 ( 0.399%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker*
*Your capital is at risk